A number of phase I and II trials evaluating everolimus in combination with TKIs and other agents are ongoing, including a phase II trial of the combination of everolimus and the EGFR tyrosine kinase inhibitor erlotinib in pretreated patients with advanced NSCLC [86] and a phase I/II trial evaluating everolimus plus carboplatin/paclitaxel and bevacizumab as first line therapy in stage IIIB/IV NSCLC [87]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.